A Phase 1b, Double-Blind Study to Investigate Safety, Tolerability, Pharmacokinetics, Efficacy, and Pharmacodynamics of Single Dose of ATI-052 in Participants with Mild to Moderate Asthma
ATI-052-ASTH-101
Phase 1 other active
Quick answer
A Phase 1b, Double-Blind Study to Investigate Safety, Tolerability, Pharmacokinetics, Efficacy, and Pharmacodynamics of Single Dose of ATI-052 in Participants with Mild to Moderate Asthma for Mild to Moderate Asthma is a Phase 1 program (other) at Aclaris Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Aclaris Therapeutics
- Indication
- Mild to Moderate Asthma
- Phase
- Phase 1
- Modality
- other
- Status
- active